Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.

ABSTRACT:

Context

Novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulaglutide.

Objective

Explore mechanisms of glucose control by tirzepatide.

Design

Post hoc analyses of fasting biomarkers and multiple linear regression analysis.

Setting

Forty-seven sites in 4 countries.

Patients or other participants

Three hundred and sixteen subjects with type 2 diabetes.

Interventions

Tirzepatide (1, 5, 10, 15 mg), dulaglutide (1.5 mg), placebo.

Main outcome measures

Analyze biomarkers of beta-cell function and insulin resistance (IR) and evaluate WL contributions to IR improvem

SUBMITTER: Thomas MK 

PROVIDER: S-EPMC7823251 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature